The mechanism involves IDO acting as a checkpoint molecule or in combination with other immune checkpoints (such as cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1) to induce T-cell suppression after tumor transformation, thereby hindering effective antitumor immune responses. The gene discussed is PDCD1; the disease is neoplasm.